 <h1>Claforan Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cefotaxime</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cefotaxime. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Claforan.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> induration at injection site, inflammation at injection site, pain at injection site, and tenderness at injection site.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cefotaxime: injection powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cefotaxime (the active ingredient contained in Claforan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking cefotaxime:</p><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach cramps or tenderness</li>
<li>black, tarry stools</li>
<li>bloating</li>
<li>chest pain</li>
<li>chills</li>
<li>diarrhea</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>difficulty with breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, or skin rash</li>
<li>increased thirst</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>nausea or vomiting</li>
<li>noisy breathing</li>
<li>pain</li>
<li>painful or difficult urination</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>tenderness</li>
<li>tightness in the chest</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Agitation</li>
<li>back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>blood in the urine or stools</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>coma</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>cracks in the skin at the corners of the mouth</li>
<li>dark urine</li>
<li>drowsiness</li>
<li>fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>fever with or without chills</li>
<li>general body swelling</li>
<li>general feeling of tiredness or weakness</li>
<li>greatly decreased frequency of urination or amount of urine</li>
<li>hallucinations</li>
<li>headache</li>
<li>irritability</li>
<li>itching of the vagina or genital area</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nosebleeds</li>
<li>pain during sexual intercourse</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>soreness or redness around the fingernails and toenails</li>
<li>stiff neck</li>
<li>swelling of the feet or lower legs</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Clay-colored stools</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cefotaxime may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Red streaks on the skin</li>
<li>swelling, tenderness, or pain at the injection site</li>
</ul><p>
<!-- end injection powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefotaxime: injectable powder for injection, intravenous solution</i></p><h3>General</h3><p>The most commonly reported side effects include injection site inflammation, pain, induration, and tenderness.<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site inflammation occurred with IV administration.  Pain, induration, and tenderness occurred with IM administration.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site inflammation, pain, induration, tenderness</p>
<p><b>Postmarketing reports</b>: Phlebitis, thrombophlebitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Signs/symptoms of pseudomembranous colitis/Clostridium difficile infection may occur during or after treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Colitis, diarrhea, nausea, vomiting</p>
<p><b>Frequency not reported</b>: Pseudomembranous colitis, abdominal pain<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash/skin rash, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Frequency not reported</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p>
<p><b>Postmarketing reports</b>: Bullous skin reactions, acute generalized exanthematous pustulosis (AGEP)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Thrombocytopenia was reported, but usually was rapidly reversible upon discontinuation.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Eosinophilia</p>
<p><b>Uncommon</b> (0.1% to 1%): Leukopenia, thrombocytopenia</p>
<p><b>Frequency not reported</b>: Neutropenia, transient leukopenia, granulocytopenia, hemolytic anemia, agranulocytosis, positive direct Coombs' tests</p>
<p><b>Postmarketing reports</b>: Hemolytic anemia, aplastic anemia, pancytopenia, bone marrow failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever</p>
<p><b>Uncommon</b> (0.1% to 1%): Drug fever</p>
<p><b>Postmarketing reports</b>: Malaise, superinfection, candidiasis, shivering, systemic reactions to lidocaine, false-positive test for urinary glucose<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Transient AST, ALT, GGT, bilirubin, and alkaline phosphatase level elevations</p>
<p><b>Frequency not reported</b>: Hepatitis, jaundice</p>
<p><b>Postmarketing reports</b>: Cholestasis, hepatic dysfunction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Convulsions</p>
<p><b>Frequency not reported</b>: Headache, dizziness, encephalopathy, impaired consciousness, abnormal movements</p>
<p><b>Postmarketing reports</b>: Seizures<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Jarisch-Herxheimer reaction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic reaction, anaphylactic shock, angioedema, allergic reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Moniliasis, vaginitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Transient blood urea nitrogen level elevations</p>
<p><b>Postmarketing reports</b>: Interstitial nephritis, transient creatinine elevations, acute renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Difficulty breathing</p>
<p><b>Postmarketing reports</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Transient lactate dehydrogenase elevations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Joint discomfort<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Potentially fatal arrhythmias, shock, hemorrhage<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Claforan (cefotaxime)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: third generation cephalosporins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Claforan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bacteremia</li>
<li>Bone infection</li>
<li>Cesarean Section</li>
<li>CNS Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +21 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefotaxime: injectable powder for injection, intravenous solution</i></p><h3>General</h3><p>The most commonly reported side effects include injection site inflammation, pain, induration, and tenderness.<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site inflammation occurred with IV administration.  Pain, induration, and tenderness occurred with IM administration.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site inflammation, pain, induration, tenderness</p><p><b>Postmarketing reports</b>: Phlebitis, thrombophlebitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Signs/symptoms of pseudomembranous colitis/Clostridium difficile infection may occur during or after treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Colitis, diarrhea, nausea, vomiting</p><p><b>Frequency not reported</b>: Pseudomembranous colitis, abdominal pain<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash/skin rash, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p><p><b>Postmarketing reports</b>: Bullous skin reactions, acute generalized exanthematous pustulosis (AGEP)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Thrombocytopenia was reported, but usually was rapidly reversible upon discontinuation.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Eosinophilia</p><p><b>Uncommon</b> (0.1% to 1%): Leukopenia, thrombocytopenia</p><p><b>Frequency not reported</b>: Neutropenia, transient leukopenia, granulocytopenia, hemolytic anemia, agranulocytosis, positive direct Coombs' tests</p><p><b>Postmarketing reports</b>: Hemolytic anemia, aplastic anemia, pancytopenia, bone marrow failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever</p><p><b>Uncommon</b> (0.1% to 1%): Drug fever</p><p><b>Postmarketing reports</b>: Malaise, superinfection, candidiasis, shivering, systemic reactions to lidocaine, false-positive test for urinary glucose<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Transient AST, ALT, GGT, bilirubin, and alkaline phosphatase level elevations</p><p><b>Frequency not reported</b>: Hepatitis, jaundice</p><p><b>Postmarketing reports</b>: Cholestasis, hepatic dysfunction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Convulsions</p><p><b>Frequency not reported</b>: Headache, dizziness, encephalopathy, impaired consciousness, abnormal movements</p><p><b>Postmarketing reports</b>: Seizures<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Jarisch-Herxheimer reaction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic reaction, anaphylactic shock, angioedema, allergic reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Moniliasis, vaginitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Transient blood urea nitrogen level elevations</p><p><b>Postmarketing reports</b>: Interstitial nephritis, transient creatinine elevations, acute renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Difficulty breathing</p><p><b>Postmarketing reports</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Transient lactate dehydrogenase elevations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Joint discomfort<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Potentially fatal arrhythmias, shock, hemorrhage<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Claforan (cefotaxime)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: third generation cephalosporins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Claforan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacteremia</li>
<li>Bone infection</li>
<li>Cesarean Section</li>
<li>CNS Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +21 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>